ArticleActa pharmacologica Sinica2018

GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.

Pei-Bin Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.